DE60123529D1 - Buprenorphin hydrochlorid enthaltende pflaster - Google Patents

Buprenorphin hydrochlorid enthaltende pflaster

Info

Publication number
DE60123529D1
DE60123529D1 DE60123529T DE60123529T DE60123529D1 DE 60123529 D1 DE60123529 D1 DE 60123529D1 DE 60123529 T DE60123529 T DE 60123529T DE 60123529 T DE60123529 T DE 60123529T DE 60123529 D1 DE60123529 D1 DE 60123529D1
Authority
DE
Germany
Prior art keywords
adhesive
fatty acid
acid ester
buprenorphine hydrochloride
buprenorphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123529T
Other languages
English (en)
Other versions
DE60123529T2 (de
Inventor
Susumu Maruo
O Hidaka
Satoshi Murakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Publication of DE60123529D1 publication Critical patent/DE60123529D1/de
Application granted granted Critical
Publication of DE60123529T2 publication Critical patent/DE60123529T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60123529T 2000-02-25 2001-02-22 Buprenorphin hydrochlorid enthaltende pflaster Expired - Lifetime DE60123529T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000049298 2000-02-25
JP2000049298A JP4659943B2 (ja) 2000-02-25 2000-02-25 塩酸ブプレノルフィン含有貼付剤
PCT/JP2001/001293 WO2001062254A1 (fr) 2000-02-25 2001-02-22 Pieces contenant de la buprenorphine chlorhydrate

Publications (2)

Publication Number Publication Date
DE60123529D1 true DE60123529D1 (de) 2006-11-16
DE60123529T2 DE60123529T2 (de) 2007-06-14

Family

ID=18571263

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123529T Expired - Lifetime DE60123529T2 (de) 2000-02-25 2001-02-22 Buprenorphin hydrochlorid enthaltende pflaster

Country Status (13)

Country Link
US (1) US7056527B2 (de)
EP (1) EP1174137B1 (de)
JP (1) JP4659943B2 (de)
KR (1) KR100709930B1 (de)
CN (1) CN1187049C (de)
AT (1) ATE341328T1 (de)
AU (1) AU782249B2 (de)
CA (1) CA2368356C (de)
DE (1) DE60123529T2 (de)
ES (1) ES2272443T3 (de)
HK (1) HK1040616B (de)
PT (1) PT1174137E (de)
WO (1) WO2001062254A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
WO2004082672A1 (ja) * 2003-03-18 2004-09-30 Hisamitsu Pharmaceutical Co., Inc. 非ステロイド系消炎鎮痛剤含有貼付剤
KR20060054346A (ko) * 2003-07-25 2006-05-22 유로-셀띠끄 소시에떼 아노님 수술후 통증의 수술전 치료
SG173326A1 (en) * 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
DE102005011517A1 (de) * 2005-03-10 2006-09-21 Grünenthal GmbH Transdermales therapeutisches System zur Verabreichung von Analgetika
US20060223786A1 (en) * 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
US20070248657A1 (en) * 2006-04-25 2007-10-25 Smith David J Multi-compartment transdermal pain control device
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
CN101612141B (zh) * 2009-07-29 2012-10-03 考司美德制药株式会社 丁丙诺啡贴剂
JP2012158572A (ja) * 2011-02-02 2012-08-23 Nitto Denko Corp 貼付製剤の製造方法
DE102011076653A1 (de) * 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
KR102014565B1 (ko) * 2011-12-12 2019-08-26 에르테에스 로만 테라피-시스테메 아게 부프레노르핀을 포함하는 경피 전달 시스템
PL2877155T3 (pl) 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
CN103893154A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 包含丁丙诺啡的透皮给药系统
JP6370802B2 (ja) * 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
JP6151935B2 (ja) * 2013-03-11 2017-06-21 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
CN110013602B (zh) * 2019-04-17 2021-10-26 杨高云 用于治疗肢端型白癜风的手套及其制备方法
US11872320B2 (en) 2021-02-25 2024-01-16 Hisamitsu Pharmaceutical Co., Inc. Method for treating osteoarthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
JPH02503672A (ja) * 1987-06-01 1990-11-01 ワーナー‐ランバート・コンパニー 水性の系における浸透促進剤としての脂肪酸およびその短鎖エステル
EP0432945A1 (de) * 1989-12-12 1991-06-19 Warner-Lambert Company Transdermales Abgabesystem zur Behandlung der Kokain- und Heroinsucht
JP2849937B2 (ja) * 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
JP2507158B2 (ja) * 1990-08-23 1996-06-12 積水化学工業株式会社 経皮吸収製剤
JP2669951B2 (ja) 1991-03-28 1997-10-29 雍憲 森本 麻薬性鎮痛剤を含有する経皮吸収組成物
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
JPH0710754A (ja) 1993-06-28 1995-01-13 Sekisui Chem Co Ltd 経皮吸収貼付剤
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
JPH1045571A (ja) * 1996-07-29 1998-02-17 Sekisui Chem Co Ltd 貼付剤

Also Published As

Publication number Publication date
AU3412201A (en) 2001-09-03
ES2272443T3 (es) 2007-05-01
JP2001233769A (ja) 2001-08-28
EP1174137A1 (de) 2002-01-23
WO2001062254A1 (fr) 2001-08-30
CN1362879A (zh) 2002-08-07
CA2368356A1 (en) 2001-08-30
HK1040616B (zh) 2006-12-29
EP1174137A4 (de) 2003-05-21
PT1174137E (pt) 2006-12-29
US7056527B2 (en) 2006-06-06
AU782249B2 (en) 2005-07-14
DE60123529T2 (de) 2007-06-14
ATE341328T1 (de) 2006-10-15
CN1187049C (zh) 2005-02-02
JP4659943B2 (ja) 2011-03-30
KR20010111591A (ko) 2001-12-19
HK1040616A1 (en) 2002-06-21
CA2368356C (en) 2009-08-25
KR100709930B1 (ko) 2007-04-24
US20020182247A1 (en) 2002-12-05
EP1174137B1 (de) 2006-10-04

Similar Documents

Publication Publication Date Title
DE60123529D1 (de) Buprenorphin hydrochlorid enthaltende pflaster
TR200103493T2 (tr) Metaloproteaz önleyicileri
ES2188907T3 (es) Dispositivo de soporte farmaceutico adecuado ppara la administracion de compuestos farmaceuticos a las superficies de las mucosas.
HRP20010779B1 (en) Pharmaceutical composition
NO2013019I2 (no) Aliskiren eller et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
AU2941900A (en) Biodegradable cellulose acetate constructions and tobacco filter
EP1325752A3 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
DE69833000D1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
IT1283102B1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
CY1108165T1 (el) ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ
KR970704695A (ko) 인돌리진 sPLA₂억제제(INDOLIZINE sPLA₂INHIBITORS)
ITMI942025A0 (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
PT1077688E (pt) Sistema terapeutico transdermico contendo pergolide
HUP0000937A2 (hu) Új zsírsav-származékok
DE69827210D1 (de) Isosorbiddinitrat enthaltendes pflaster
SE0003476D0 (sv) Compounds
ATE131736T1 (de) Boulekugel sowie verfahren zu deren herstellung
DE69904585D1 (de) Verfahren zur Herstellung von Mometason Furoat
AU2001262993A1 (en) Relevant search rankings using high refresh-rate distributed crawling
DE69925007D1 (de) System zur oralen wirkstoffabgabe zur steigerung der bioverfügbarkeit von aktiviertem glycyrrhetin
EP2127644B1 (de) Gelzusammensetzung für medizinisches Material oder Hygienematerial, Formteil davon und Klebstoffmaterial oder Klebstoffpräparat, das diese Zusammensetzung einsetzt
JPS5764613A (en) Soft plaster
SE9904483D0 (sv) New use
FI982743A0 (fi) Keilaradan rakennuselementti ja keilarata

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: MARUO, SUSUMU, TACHIKAWA, TOKYO, JP

Inventor name: HIDAKA, O., TACHIKAWA, TOKYO, JP

Inventor name: MURAKAMI, SATOSHI, HINO, TOKYO, JP

8364 No opposition during term of opposition